Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Schuster

Showing results (501-510 of 630) with videos related to

Pageof 63
Sort By:
Blood|May 24, 2003
Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantationGinna G Laport, Bruce L Levine, Edward A Stadtmauer, et al.
British Journal of Haematology|April 12, 2017
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinibJeffrey A Jones, Peter Hillmen, Steven Coutre, et al.
Leukemia|June 30, 2018
LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targetingLorenz Thurner, Sylvia Hartmann, Natalie Fadle, et al.
Leukemia & Lymphoma|November 18, 2022
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 studyJohn Kuruvilla, Philippe Armand, Mehdi Hamadani, et al.
Blood Advances|July 23, 2024
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucelNausheen Ahmed, William Wesson, Forat Lutfi, et al.
The New England Journal of Medicine|December 12, 2017
Chimeric Antigen Receptor T Cells in Refractory B-Cell LymphomasStephen J Schuster, Jakub Svoboda, Elise A Chong, et al.
Blood Advances|November 10, 2022
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapyKitsada Wudhikarn, Ana Alarcon Tomas, Jessica R Flynn, et al.
Cancer Medicine|May 16, 2026
Investigating Associations Between Psychological Distress and Changes in Peripheral Blood Monocytes in Patients With CLL/SLL Managed With Active SurveillanceCarolyn Y Fang, Alexander W MacFarlane, Henry C H Fung, et al.
Blood Advances|June 24, 2026
Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium AnalysisKitsada Wudhikarn, Maria Bromberg, Jamie Brower, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial resultsJohn P Leonard, Morton Coleman, Jamie C Ketas, et al.
Pageof 63

Showing results (501-510 of 630) with videos related to

Sort By:
Pageof 63
Blood|May 24, 2003
Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantationGinna G Laport, Bruce L Levine, Edward A Stadtmauer, et al.
British Journal of Haematology|April 12, 2017
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinibJeffrey A Jones, Peter Hillmen, Steven Coutre, et al.
Leukemia|June 30, 2018
LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targetingLorenz Thurner, Sylvia Hartmann, Natalie Fadle, et al.
Leukemia & Lymphoma|November 18, 2022
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 studyJohn Kuruvilla, Philippe Armand, Mehdi Hamadani, et al.
Blood Advances|July 23, 2024
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucelNausheen Ahmed, William Wesson, Forat Lutfi, et al.
The New England Journal of Medicine|December 12, 2017
Chimeric Antigen Receptor T Cells in Refractory B-Cell LymphomasStephen J Schuster, Jakub Svoboda, Elise A Chong, et al.
Blood Advances|November 10, 2022
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapyKitsada Wudhikarn, Ana Alarcon Tomas, Jessica R Flynn, et al.
Cancer Medicine|May 16, 2026
Investigating Associations Between Psychological Distress and Changes in Peripheral Blood Monocytes in Patients With CLL/SLL Managed With Active SurveillanceCarolyn Y Fang, Alexander W MacFarlane, Henry C H Fung, et al.
Blood Advances|June 24, 2026
Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium AnalysisKitsada Wudhikarn, Maria Bromberg, Jamie Brower, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial resultsJohn P Leonard, Morton Coleman, Jamie C Ketas, et al.
Pageof 63